SEPHS1 Antibody

What is SEPHS1 and why is it important in biological research?

SEPHS1 (Selenophosphate Synthetase 1) is a 392 amino acid protein (approximately 43 kDa) that synthesizes selenophosphate from selenide and ATP. It belongs to the selenophosphate synthetase family and is one of two mammalian homologs of the eubacteria selenophosphate synthetase protein SelD . SEPHS1 has been implicated in the maintenance of redox homeostasis in chondrocytes, and its deficiency plays a causal role in the progression of osteoarthritis . Recent research has demonstrated that SEPHS1 is critical for cell survival, as its downregulation in human umbilical vein cells (HUVECs) leads to cell death . The protein's importance extends to developmental processes, with recent evidence showing that de novo missense variants in exon 9 of SEPHS1 cause developmental delay, growth problems, hypotonia, and dysmorphic features .

How do I select the appropriate SEPHS1 antibody for my research?

Selection should be based on multiple factors including:

• Experimental application: Different antibodies show varying performance in applications such as WB, IHC, and IF. For example, antibody 16635-1-AP has been validated for WB (1:2000-1:12000), IHC (1:20-1:200), and IF-P (1:200-1:800) .

• Species reactivity: Confirm reactivity with your target species. Many SEPHS1 antibodies react with human, mouse, and rat samples, but cross-reactivity varies between products .

• Target region: Some antibodies target full-length SEPHS1, while others target specific regions:

  • N-terminal regions (AA 1-96, AA 1-200)

  • C-terminal regions

  • Full-length protein (AA 1-392)

• Validation data: Review Western blot images, IHC staining patterns, and published literature citing the antibody to ensure it detects the expected ~43 kDa band and proper subcellular localization .

What are the recommended protocols for SEPHS1 antibody validation in knockout/knockdown models?

For rigorous validation:

• Generate appropriate controls: Use CRISPR/Cas9 or siRNA to create SEPHS1 knockout or knockdown cells as demonstrated in the literature where SEPHS1 deficiency was confirmed by both immunocytochemistry and Western blot analysis .

• Recovery validation: Include a rescue construct with silent mutations in the guide RNA target site to confirm specificity. As shown in Figure 1 from search result , this approach demonstrates that protein expression can be recovered, confirming antibody specificity .

• Multiple detection methods: Validate using both Western blot and immunofluorescence techniques. For Western blot, use appropriate positive controls such as Jurkat cells, HepG2 cells, mouse liver tissue, or T-47D cells, which have been shown to express detectable levels of SEPHS1 .

• Quantitative assessment: Compare band intensity between wild-type, knockout, and rescue cells using densitometry to quantify the degree of knockdown and recovery .

How can I optimize antigen retrieval for SEPHS1 immunohistochemistry?

Based on published protocols:

• Buffer selection: Primary recommendation is to use TE buffer pH 9.0 for optimal antigen retrieval when working with tissues such as human lung cancer tissue .

• Alternative method: If TE buffer is ineffective, citrate buffer pH 6.0 may be used as an alternative approach .

• Optimization strategy:

  • Begin with recommended dilution ranges (1:20-1:200)

  • Test both suggested buffers on serial sections of the same tissue

  • Include positive control tissues (human lung cancer tissue has been verified)

  • Gradually adjust incubation times and temperatures if initial results are suboptimal

• Tissue-specific considerations: Different tissues may require modified protocols. For example, detection in human placenta tissue for IF-P applications may require different conditions than those for lung cancer tissue in IHC .

How can SEPHS1 antibodies be utilized to study redox homeostasis and oxidative stress?

SEPHS1 antibodies can be effectively employed to investigate redox pathways through several methodologies:

• Co-localization studies: Use dual immunofluorescence with SEPHS1 antibodies (1:200-1:800 dilution) alongside markers for superoxide dismutase (SOD1, SOD3) to visualize their spatial relationship, as research has demonstrated that SEPHS1 deficiency decreases expression of these enzymes .

• Protein-protein interaction analysis:

  • Immunoprecipitation followed by Western blot to detect interactions between SEPHS1 and redox-regulating proteins

  • Proximity ligation assay to visualize in situ interactions in fixed cells or tissues

• Expression correlation analysis: Compare SEPHS1 levels with oxidative stress markers in various experimental conditions:

  • After treatment with ROS inducers (H₂O₂, paraquat)

  • In the presence of antioxidants (N-acetyl cysteine, SOD)

  • Following inhibition of enzymes like xanthine oxidase or NADPH oxidase with allopurinol or GKT137831, respectively

• Pathway inhibition studies: Research has shown that SEPHS1 deficiency leads to superoxide accumulation through multiple mechanisms. Use SEPHS1 antibodies to monitor protein levels while targeting specific pathways with:

  • Allopurinol (XO inhibitor)

  • GKT137831 (NOX1 and 4 inhibitor)

  • VAS2780 (NOX2 inhibitor)

  • ML171 (NOX1 inhibitor)

  • Mito-TEMPO (mitochondrial superoxide scavenger)

What approaches should be used to study SEPHS1's role in pathological conditions?

Based on recent findings connecting SEPHS1 to various pathologies:

• Osteoarthritis research:

  • Use IHC with anti-SEPHS1 antibodies on cartilage samples to assess expression patterns

  • Compare SEPHS1 levels between healthy and osteoarthritic tissues

  • Correlate SEPHS1 levels with markers of chondrocyte stress and cartilage degradation

• Developmental disorders:

  • Analyze SEPHS1 variants (particularly in exon 9) in patient samples

  • Use patient-derived cells to examine how variants affect SEPHS1 protein expression, stability, and function

  • Combine with structural modeling to understand how variants at residues like Arg371 might affect protein-protein interactions without impacting enzyme stability and folding

• Cancer studies:

  • Examine SEPHS1 expression in different cancer types using tissue microarrays

  • Investigate correlation between SEPHS1 levels and proliferation markers

  • Study the impact of SEPHS1 inhibition on cancer cell migration, invasion, and angiogenesis

• Experimental endpoints:

  • Cell proliferation assays

  • ROS measurement using fluorescent probes

  • Expression analysis of selenoproteins and redox-related genes

  • Analysis of cell cycle arrest at G2/M phase

  • Quantification of DNA damage through gamma H2AX foci formation

How can I minimize background and optimize signal-to-noise ratio when using SEPHS1 antibodies?

Common challenges and solutions include:

• High background in Western blot:

  • Optimize blocking (5% non-fat milk or BSA in TBST)

  • Increase washing steps (3-5 times for 5-10 minutes each)

  • Titrate primary antibody concentration (start with higher dilutions: 1:2000-1:12000 for WB)

  • Reduce secondary antibody concentration if necessary

  • Use freshly prepared buffers

• Weak or absent signal:

  • Verify sample preparation (proper lysis buffer, protease inhibitors)

  • Confirm protein loading (20-30 μg for cell lysates)

  • Consider using positive control samples like Jurkat cells, HepG2 cells, or T-47D cells

  • Decrease antibody dilution or increase incubation time

  • Enhance detection using more sensitive substrates

• Non-specific bands:

  • Use higher antibody dilutions

  • Include additional blocking steps

  • Pre-adsorb antibody with non-specific proteins

  • Confirm using knockout/knockdown controls

  • Verify expected molecular weight (43 kDa for SEPHS1)

What are the critical variables in experimental design when studying SEPHS1 and superoxide interactions?

Based on published research methodologies:

• ROS detection methods selection:

  • CM-DCFDA staining for total ROS measurement

  • DHE staining for superoxide-specific detection

  • roGFP-Orp1 probe transfection for cytosolic H₂O₂ measurement

• Pathway inhibitor concentrations and timing:

  • Carefully titrate inhibitors like allopurinol, GKT137831, VAS2780, and ML171

  • Include both short-term (acute) and long-term (chronic) treatments

  • Monitor cell viability alongside SEPHS1 and ROS measurements

• Quantification approaches:

  • Use flow cytometry for population-level analysis

  • Employ fluorescence microscopy with digital image analysis for spatial information

  • Perform Western blot with densitometry for protein level comparisons

• Critical controls:

  • Include antioxidant treatments (SOD, NAC, catalase) as positive controls for ROS reduction

  • Use pro-oxidant treatments as positive controls for ROS induction

  • Test multiple cell types as SEPHS1 effects may vary between tissues

How have recent structural insights changed our understanding of SEPHS1 function?

Recent structural studies have revealed crucial insights:

What are the emerging methodologies for studying SEPHS1 in developmental contexts?

Given recent discoveries linking SEPHS1 variants to developmental disorders:

• Patient-derived models:

  • iPSC generation from individuals with SEPHS1 variants

  • Differentiation into relevant cell types (neurons, chondrocytes)

  • CRISPR-based introduction of specific variants (p.Arg371Trp, p.Arg371Gln, p.Arg371Gly) into control cell lines

• Advanced imaging techniques:

  • Live-cell imaging to track SEPHS1 dynamics during development

  • Super-resolution microscopy to examine SEPHS1 localization at subcellular level

  • Correlative light and electron microscopy to understand contextual relationships

• Multi-omics approaches:

  • Integrate transcriptomics, proteomics, and metabolomics data

  • Focus on retinoic acid signaling pathways, which have been implicated in SEPHS1-related developmental disorders

  • Map the entire selenoprotein network in developmental contexts

• Evolutionary perspectives:

  • Comparative studies of SEPHS1 across species to identify conserved functional domains

  • Examination of SEPHS1's evolutionary relationship with other selenophosphate synthetases

  • Analysis of selenoprotein expression patterns across developmental stages